DexCom has barely scratched the surface of its niche in the diabetes market. As a result of industry challenges, the stock's valuation has now come down. But from here, the stock looks well-positioned ...

Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient ...

Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...

Dexcom develops continuous glucose monitoring (CGM) devices. Diabetic patients use these to track their glucose levels in ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

The multi-billion dollar CGM market is expected to experience substantial, double-digit percentage growth over the next five ...

DexCom has partnered with Google Life Sciences to develop the next generation of DexCom's CGM -- a device that is "the size of a dime", less expensive than current CGMs, and that the companies hope ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and ...

DexCom (DXCM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...